The life sciences industry has been challenged over the last several years with an economic environment that is not conducive to breeding new innovation. While things are slowly improving, reports abound of fewer investments in life science start-ups and fewer active investors in the sector. Many new ideas aren’t being developed—because the financial climate can’t support them. This could result in an innovation bottleneck in our industry pipeline as a whole, and one could argue that the next generation of new medicines, medical devices, and other healthcare products is at risk if we don’t do something to improve the environment in which they develop.
To read the full, original article click on this link: Big Pharma’s Role in Supporting the Life Science Innovation Ecosystem | Xconomy
